Search clinical trials for: Protein Kinase Inhibitors

Total 73746 results

Peng Liu

Recruiting

Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Peking Union Medical College Hospital

Recruiting

Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Biliary Tract Neoplasms | Immunotherapy

China
NiKang Therapeutics, Inc.
Pfizer

Recruiting

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Neoplasms | Kidney Cancer | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Neoplasms by Site | Kidney Diseases | Urologic Diseases | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Recurrent... and other conditions

United States
Sun Yat-sen University

Not yet recruiting

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

China
Dartmouth-Hitchcock Medical Center

Recruiting

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor (GERTRUDE)

Advanced Breast Cancer

United States
Technical University of Munich

Recruiting

Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease

Idiopathic Parkinson´s Disease

Germany
Fundaleu

Recruiting

Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase (AST)

CML

Argentina
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Dana-Farber Cancer Institute
Sanofi; National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Chronic Graft Versus Host Disease | Lung Diseases | Bronchiolitis Obliterans | Bronchiolitis Obliterans Syndrome

United States
Chen Miao

Recruiting

Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA

Warm Autoimmune Hemolytic Anemia

China
Zhejiang Cancer Hospital

Recruiting

Lenvatinib Combined With Tislelizumab and TACE Applied as Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma With High-risk Recurrence Factors

Hepatocellular Carcinoma | Oxaliplatin | TACE | Lenvatinib | Tislelizumab | Pharmorubicin

China
Grupo Espanol de Tumores Neuroendocrinos
MFAR; ITM Oncologics GmbH

Recruiting

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. (LEVEL)

Thymus Neoplasms | Neuroendocrine Tumors | Lung Neuroendocrine Neoplasm

Spain, Italy, France
Institute of Hematology & Blood Diseases Hospital

Recruiting

Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM (ZBR)

Waldenstrom Macroglobulinemia

China
Guangxi Medical University

Not yet recruiting

Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation (PREVENT-2)

Recurrence | Hepatocellular Carcinoma | Immune Checkpoint Inhibitor

China
Pfizer
Arvinas Estrogen Receptor, Inc.

Recruiting

A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer (VERITAC-3)

Breast Cancer

United States, China, Spain, Hungary, Japan, Australia, Brazil, Italy, Slovakia, Switzerland
Erasca, Inc.

Recruiting

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations (SEACRAFT-1)

Advanced or Metastatic Solid Tumors

United States, Canada, Korea, Republic of, United Kingdom, Australia
Zhejiang Cancer Hospital

Not yet recruiting

Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma
Asan Medical Center
Korean Cancer Study Group; Boryung Pharmaceutical Co., Ltd

Recruiting

A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer (BRISK)

Advanced Solid Tumors | Metastatic Cancer | Solid Tumors

Korea, Republic of
AGO Research GmbH

Not yet recruiting

Pembrolizumab in Combination With Lenvatinib in Patients With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy (PIERCE)

Recurrent Vulvar Cancer | Persistent Vulvar Cancer | Metastatic Vulva Cancer | Locally Advanced Vulvar Cancer
Asan Medical Center

Recruiting

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumors

Korea, Republic of
Assistance Publique - Hôpitaux de Paris
Laboratoire EISAI

Not yet recruiting

Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma (Ta-Len-Tra)

Hepatocellular Carcinoma Non-resectable

France
Shanghai Kechow Pharma, Inc.

Not yet recruiting

Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study

Non-small-cell Lung Cancer
Ruijin Hospital

Recruiting

Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT

PCNSL

China
Xijing Hospital

Recruiting

Exploring the Molecular Mechanism Based on KIT Mutation (EMMBKM)

GIST

China
Fudan University

Recruiting

Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10) (CASTLE-10)

Hepatocellular Carcinoma

China
Fujian Cancer Hospital

Not yet recruiting

A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses

Hepatocellular Carcinoma
Fudan University

Recruiting

Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09) (CASTLE-09)

Gastric Cancer Metastatic to Liver

China
Memorial Sloan Kettering Cancer Center
Seagen Inc.

Recruiting

A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain

Metastatic Breast Cancer

United States
SWOG Cancer Research Network
National Cancer Institute (NCI); Incyte Corporation; Ipsen; BeiGene

Recruiting

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 3b Follicular Lymphoma | Transformed Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

United States
Liaoning Tumor Hospital & Institute

Not yet recruiting

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Diffuse Large B Cell Lymphoma

China
AbbVie

Recruiting

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS)

Hidradenitis Suppurativa

United States, Japan, Australia, Canada, Korea, Republic of, New Zealand, Puerto Rico, Spain, Taiwan, Austria, Italy, Hungary, Bulgaria, Israel, Croatia, Netherlands, Switzerland, Germany, Portugal, Slovakia, France, United Kingdom, Czechi... and more
Fudan University

Not yet recruiting

A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer

HR+/HER2-breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1 Combined With Osimertinib Mesylate Tablets in Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
RenJi Hospital

Recruiting

A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC

Fumarate Hydratase Deficient Renal Cell Carcinoma

China
Se Jun Park

Recruiting

Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations

Cancer

Korea, Republic of
Adam Kittai

Recruiting

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed Non-Hodgkin Lymphoma | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Recurrent Transformed... and other conditions

United States
Stephen Chan Lam

Recruiting

CXD101 in Immunotherapy-related Liver Cancer

HCC

Hong Kong
Genfit

Recruiting

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma

Cholangiocarcinoma

United States, Puerto Rico
QuantumLeap Healthcare Collaborative

Recruiting

PRE-I-SPY Phase I/Ib Oncology Platform Program (PRE-I-SPY-PI)

Solid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditions

United States
Telix International Pty Ltd
Merck KGaA, Darmstadt, Germany

Recruiting

Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Advanced Solid Tumor | Solid Tumor, Adult | Advanced Renal Cell Carcinoma

Australia
Berinstein, Jeffrey

Recruiting

A Trial for Acute Severe Ulcerative Colitis

Ulcerative Colitis Acute

United States
Avenzo Therapeutics, Inc.

Recruiting

Study of ARTS-021 in Patients With Advanced Solid Tumors

Solid Tumors

United States
AIPING ZHOU

Recruiting

Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

Esophagus Squamous Cell Carcinoma

China
Hoffmann-La Roche

Recruiting

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study (UmbrellaMAX)

Cancer

Korea, Republic of, United Kingdom, Japan, Costa Rica, Belgium, Taiwan, Russian Federation, Mexico, Poland, France
Sun Yat-sen University

Recruiting

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer

Gastric Cancer

China
Therapeutic Advances in Childhood Leukemia Consortium

Not yet recruiting

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Neurofibromatosis 1 | JMML | Leukemia, Juvenile Myelomonocytic | JCML | CBL Syndrome
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...

Not yet recruiting

Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma (PULSAR)

Classic Kaposi Sarcoma | Kaposi Sarcoma | Refractory Kaposi Sarcoma
Nationwide Children's Hospital
Novartis

Not yet recruiting

Study of Ribociclib and Everolimus in HGG and DIPG

Glioblastoma | Glioblastoma Multiforme | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | WHO Grade IV Glioma

United States, Australia, United Kingdom, Canada, Germany, Netherlands
Peking Union Medical College Hospital

Recruiting

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

Hepatocellular Carcinoma

China

Search clinical trials for: Protein Kinase Inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations